BetterLife Pharma faces lawsuit over convertible debenture conversion

BetterLife Pharma said director Steven Sangha filed a civil claim seeking conversion of a June 2026 convertible debenture into 33,333,333 shares and 33,333,333 warrants. The company said it plans to contest the claim.